Oral Antibiotic for Non-Healing Wound
For an adult with a non-healing, possibly infected wound, start with clindamycin 300-450 mg three times daily OR trimethoprim-sulfamethoxazole (TMP-SMX) 1-2 double-strength tablets twice daily for 5-10 days, with the choice depending on local MRSA prevalence and wound characteristics.
Clinical Decision Algorithm
Step 1: Determine Wound Characteristics
Purulent vs. Non-purulent:
- Purulent wound (drainage, exudate, no drainable abscess): Empirically cover CA-MRSA 1, 2
- Non-purulent wound (no drainage/exudate, no abscess): Start with β-hemolytic streptococci coverage; add MRSA coverage only if patient fails to respond to β-lactam therapy or has systemic toxicity 1
Step 2: Select Antibiotic Based on Coverage Needed
For MRSA Coverage (purulent wounds or failed β-lactam therapy):
Clindamycin 300-450 mg PO three times daily (A-II evidence) 1
- Advantage: Also covers β-hemolytic streptococci, so monotherapy is sufficient
- Caveat: Check local resistance rates; avoid if erythromycin resistance >10% due to inducible resistance risk 3
TMP-SMX 1-2 double-strength tablets twice daily (A-II evidence) 1, 2
- Advantage: Bactericidal, effective against CA-MRSA
- Limitation: Poor streptococcal coverage—must add amoxicillin if dual coverage needed 1
Doxycycline 100 mg twice daily (A-II evidence) 1, 2
- Alternative option with similar efficacy
- Must combine with β-lactam (e.g., amoxicillin) for streptococcal coverage 1
For Non-purulent Wounds (streptococcal coverage):
Step 3: Duration of Therapy
5-10 days is standard, individualized by clinical response 1, 2. The 2011 IDSA guidelines consistently recommend this duration across multiple references, emphasizing that treatment should continue until infection resolves, not necessarily until wound heals.
Key Clinical Considerations
When antibiotics are actually indicated: Antibiotics are necessary when the wound shows signs of infection with systemic involvement, extensive disease, rapid progression with cellulitis, comorbidities/immunosuppression, or failure to heal with local wound care alone 1, 2. A recent high-quality RCT demonstrated that for simple abscesses <5 cm, antibiotics (clindamycin or TMP-SMX) improved cure rates from 68.9% to 83.1% compared to drainage alone 5.
Common pitfall to avoid: Do not use rifampin as monotherapy or adjunctive therapy for skin and soft tissue infections—it is explicitly not recommended 1. Despite theoretical benefits, there is no evidence supporting its use and resistance develops rapidly.
Culture guidance: Obtain wound cultures if the patient has severe infection, systemic illness, has failed initial treatment, or if there's concern for outbreak 1, 2. This allows de-escalation or modification based on susceptibility data.
Special consideration for diabetic foot ulcers: While doxycycline has MMP-inhibiting properties that may theoretically benefit chronic diabetic wounds 6, the primary indication remains antimicrobial coverage. For diabetic foot infections specifically, empirical broad-spectrum coverage is often needed initially, with therapy duration of 1-2 weeks for mild infections and 2-4 weeks for moderate-severe infections 7.
Practical Implementation
First-line choice: Clindamycin monotherapy provides the simplest regimen with both MRSA and streptococcal coverage, making it ideal when wound characteristics are unclear 1.
Cost-effective alternative: TMP-SMX plus amoxicillin provides equivalent coverage at lower cost, though requires two medications 1.
If patient fails initial therapy: Discontinue antibiotics for several days, obtain optimal culture specimens, then restart based on culture results 7.